ProKidney Corp
Change company Symbol lookup
Select an option...
PROK ProKidney Corp
ABB Abb Ltd
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
ACEL Accel Entertainment Inc
USLM United States Lime & Minerals Inc
BWEN Broadwind Inc
EQIX Equinix Inc
TXMD TherapeuticsMD Inc
Go

Company profile

ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The Company is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The Company is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

The symbol you entered, DNAC, changed to PROK.

Closing Price
$7.42
Day's Change
0.38 (5.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.66
Day's Low
6.23
Volume
(Below Average)
Volume:
35,775

10-day average volume:
40,242
35,775

Display:

Providers:

UpdateCancel
6 providers
July 20, 2022
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

EQNX::TICKER_START (NASDAQ:PROK), EQNX::TICKER_END ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on Chronic Kidney Disease (CKD), announces the appointment of...(Globe Newswire)

July 12, 2022
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

EQNX::TICKER_START (NASDAQ:PROK),(NASDAQ:DNAC), EQNX::TICKER_END -- ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT(TM) -- PIPE is led by a $125 million investment from Social Capital...(Globe Newswire)

July 08, 2022
Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders

Social Capital Suvretta Holdings Corp. III ("SCS") today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and...(BusinessWire)

June 23, 2022
ProKidney Corroborates the Mechanism of Action of REACT(TM) with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

EQNX::TICKER_START (NASDAQ:DNAC), EQNX::TICKER_END ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD)...(Globe Newswire)

June 15, 2022
ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT(TM) Manufacturing Costs

EQNX::TICKER_START (NASDAQ:DNAC), EQNX::TICKER_END ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced an update on manufacturing efficiency and...(Globe Newswire)

June 07, 2022
Observed Safety Profile Supports Bilateral Dosing of ProKidney's REACT(TM) - 007 Update

EQNX::TICKER_START (NASDAQ:DNAC), EQNX::TICKER_END Potential for Amplified Therapeutic Effect of REACT(TM) with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 (Globe Newswire)

May 20, 2022
ProKidney to present at upcoming investor conferences

EQNX::TICKER_START (NASDAQ:DNAC), EQNX::TICKER_END ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD)...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.